| __timestamp | Blueprint Medicines Corporation | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 6795238 |
| Thursday, January 1, 2015 | 14456000 | 7454247 |
| Friday, January 1, 2016 | 19218000 | 10345862 |
| Sunday, January 1, 2017 | 27986000 | 16984203 |
| Monday, January 1, 2018 | 47928000 | 16187290 |
| Tuesday, January 1, 2019 | 96388000 | 9299233.54 |
| Wednesday, January 1, 2020 | 157743000 | 19232000 |
| Friday, January 1, 2021 | 195293000 | 23611000 |
| Saturday, January 1, 2022 | 237374000 | 26700000 |
| Sunday, January 1, 2023 | 295141000 | 28215000 |
| Monday, January 1, 2024 | 359272000 |
Cracking the code
In the competitive world of biotechnology, managing expenses is crucial for success. Over the past decade, Blueprint Medicines Corporation and Summit Therapeutics Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses.
Blueprint Medicines has seen a staggering increase in SG&A expenses, growing nearly 3,700% from 2014 to 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Summit Therapeutics has maintained a more conservative growth, with expenses increasing by approximately 315% over the same period.
This divergence highlights different strategic approaches: Blueprint's focus on rapid growth and market penetration versus Summit's more measured expansion. Investors and industry watchers should consider these trends when evaluating the long-term sustainability and strategic direction of these companies.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Summit Therapeutics Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Blueprint Medicines Corporation
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Blueprint Medicines Corporation
Intra-Cellular Therapies, Inc. vs Blueprint Medicines Corporation: SG&A Expense Trends
Summit Therapeutics Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Comparing Innovation Spending: Summit Therapeutics Inc. and Blueprint Medicines Corporation
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Amicus Therapeutics, Inc.
Summit Therapeutics Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Mesoblast Limited
Blueprint Medicines Corporation or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?